Safety, Efficacy and Treatment Patterns of rIX‐FP in Previously Untreated Paediatric Haemophilia B Patients: A Retrospective Chart Review in Japan

Documenti analoghi

• Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A
  di: Johnny Mahlangu, et al.
  Pubblicazione: (2025)
• TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
  di: Kagehiro Amano, et al.
  Pubblicazione: (2025)
• Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State
  di: Yuki Kawasaki, et al.
  Pubblicazione: (2025)
• Real‐World Data on Patients With Acquired Haemophilia A in Japan Undergoing Rehabilitation or With Low Activities of Daily Living Scores: The ORIHIME II Study
  di: Yoshiyuki Ogawa, et al.
  Pubblicazione: (2024)
• Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B
  di: Antonio Coppola, et al.
  Pubblicazione: (2024)